Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | GGH | Q92820 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9229673 | 0.84 | FOLH1 (0.48) | GRIK1GRIK2FOLH1CYP2C19CPA1 | |
| SCHEMBL4122899 | 0.78 | GRIK1 (0.35) | GRIK1GRIK2FOLH1CYP2C19CPA1 | |
| SCHEMBL20201438 | 0.76 | ALDH1A1 (0.39) | CYP2C19CPA1 | |
| SCHEMBL4117495 | 0.75 | POLB (0.38) | GRIK1GRIK2CYP2C19CPA1MAPT | |
| SCHEMBL2988982 | 0.72 | FOLH1 (0.43) | FOLH1GGH | |
| SCHEMBL4341072 | 0.70 | FOLH1 (0.41) | FOLH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4007537 | 0.70 | FOLH1 (0.46) | FOLH1GGHMAPT | |
| Ammonia Solution, Strong SCHEMBL27862237 | 0.68 | FOLH1 (0.40) | FOLH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31636 | 0.68 | GRIK1 (0.48) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL2536422 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147219-A1 | ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147219-A1 | ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH | ENO1, ECE1, ECI1 | GRIK1 1845/4885GRIK2 2906/4885FOLH1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.